P*t* De Ig
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
p*t* de ig
Diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (MYC-R) carries an unfavorable outcome. We explored the prognostic value of the MYC translocation partner gene in a series of MYC-R de novo DLBCL patients enrolled in first-line prospective clinical trials (Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association) and treated with rituximab-anthracycline-based chemotherapy. A total of 774 DLBCL cases characterized for cell of origin by the Hans classifier were analyzed using fluorescence in situ hybridization with BCL2, BCL6, MYC, immunoglobulin (IG)K, and IGL break-apart and IGH/MYC, IGK/MYC, and IGL/MYC fusion probes. MYC-R was observed in 51/574 (8.9%) evaluable DLBCL cases. MYC-R cases were predominantly of the germinal center B-cell-like subtype 37/51 (74%) with no distinctive morphologic and phenotypic features. Nineteen cases were MYC single-hit and 32 cases were MYC double-hit (MYC plus BCL2 and/or BCL6) DLBCL. MYC translocation partner was an IG gene in 24 cases (MYC-IG) and a non-IG gene (MYC-non-IG) in 26 of 50 evaluable cases. Noteworthy, MYC-IG patients had shorter overall survival (OS) (P = .0002) compared with MYC-negative patients, whereas no survival difference was observed between MYC-non-IG and MYC-negative patients. In multivariate analyses, MYC-IG predicted poor progression-free survival (P = .0051) and OS (P = .0006) independently from the International Prognostic Index and the Hans classifier. In conclusion, we show in this prospective randomized trial that the adverse prognostic impact of MYC-R is correlated to the MYC-IG translocation partner gene in DLBCL patients treated with immunochemotherapy. These results may have an important impact on the clinical management of DLBCL patients with MYC-R who should be routinely characterized according to MYC partner gene. These trials are individually registered at www.clinicaltrials.gov as #NCT00144807, #NCT01087424, #NCT00169143, #NCT00144755, #NCT00140660, #NCT00140595, and #NCT00135499.
Below, we give you some fresh post ideas to try for your Instagram brand account. They cover the different types of content: in-feed, Stories, Live and IGTV. Some of these will be easy to implement while others will take some preplanning. The idea is to introduce new types of content to your account so your audience will keep up their active engagement.
For brands, you could also choose a challenge format that encourages your audience to participate and post their own take on the photo challenge. You can also use unique Instagram hashtags to further drive engagement with your challenge.
Pro tip: The idea of this post type is to build anticipation and expectation with your audience. There are many photo challenges out there for you to grab ideas from but you can also just create your own and announce it in your post.
In line with great captioned copywriting, we turn to the publishing industry for our next post idea. When your business is built on great content, be it photos, words or videos, it extends to your social media presence.
The New York Times used a gallery post to create a photo essay, pulled quotes from the piece and a caption that combine to tell a story on sexual assault in the military. The summary is there in the caption and for those who are interested in reading the full piece, a link is provided in the profile.
Do you launch new products or services on Instagram? Instead of directly announcing a new product, use Stories and posts to drive interest. Build up anticipation through teaser photos, videos and question stickers.
This is a spin on the social media takeover concept and a good idea for those who are hesitant at handing the virtual account keys over to a stranger. Use Stories to conduct Q&A interviews with guests. Add an extra layer of engagement to the Q&A by asking your followers for questions and answering them in a new Story.
Domino Magazine used Stories to feature designers. It mixed content like a pre-created question Story with a casual video where they answered the question. This format continued for each question that they put into the Story. At the end of it, they asked followers who they thought would be a good interviewee for the next feature.
Pro tip: Make sure you have someone else behind the phone who can read through comments and questions. If you have an active account, a second person would come in very handy for moderation.
The Integrative Genomics Viewer (IGV) is a high-performance, easy-to-use, interactive tool for the visual exploration of genomic data. It supports flexible integration of all the common types of genomic data and metadata, investigator-generated or publicly available, loaded from local or cloud sources.
Development of IGV has been supported by funding from the National Cancer Institute (NCI) of the National Institutes of Health, the Informatics Technology for Cancer Reserarch (ITCR) of the NCI, and the Starr Cancer Consortium.
In 2018, a total of 12,474 cases of hepatitis A were reported in the United States, but due to underreporting, the actual number of cases is likely around 24,900 (1). Incidence decreased more than 95% from 1995 to 2011. Reported cases have increased dramatically since 2016, when large person-to-person outbreaks began occurring.
For more information about assessing risk for hepatitis A, refer to Table 3 in Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.
Most (70%) of infections in children younger than age 6 are not accompanied by symptoms. When symptoms are present, young children typically do not have jaundice; most (>70%) older children and adults with HAV infection have this symptom (7,8).
In contaminated food, HAV is killed when exposed to temperatures of >185 degrees F (>85 degrees C) for 1 minute (13). However, the virus can still be spread from cooked food that is contaminated after cooking. Freezing does not inactivate HAV.
Vaccination with the full, two-dose series of hepatitis A vaccine is the best way to prevent infection. Hepatitis A vaccine has been licensed in the United States for use in people 1 year of age and older. Additional guidance is available in Recommendations of the ACIP.
Although no known harm is associated with giving hepatitis A vaccine to infants, the hepatitis A vaccine dose(s) administered prior to 12 months of age might result in a suboptimal immune response, particularly in infants with passively acquired maternal antibody (18,19). Therefore, hepatitis A vaccine dose(s) administered at
The exact duration of protection against hepatitis A virus infection after vaccination is unknown. Anti-HAV has been shown to persist for at least 20 years in most people receiving the 2-dose series as infants
Yes. Hepatitis B, diphtheria, poliovirus (oral and inactivated), tetanus, typhoid (oral and intramuscular), cholera, Japanese encephalitis, rabies, and yellow fever vaccines can be given at the same time that hepatitis A vaccine is given (25). In studies among young children, simultaneous administration of hepatitis A vaccine did not affect the immunogenicity or reactogenicity of diphtheria-tetanus-acellular pertussis; inactivated polio; measles, mumps, rubella (MMR); hepatitis B; and Haemophilus influenzae type b vaccines (26,27,28).
Ideally, doses of vaccine in a series come from the same manufacturer; however, if this is not possible or if the manufacturer of doses given previously is unknown, providers should administer the vaccine that they have available (25). The dose should be considered valid and does not need to be repeated.
Yes. Pregnant women should be vaccinated for the same indications as non-pregnant women. Unvaccinated or partially vaccinated pregnant adolescents should receive catch-up hepatitis A vaccination. See Adult Immunization Schedule by Medical and Other Indications. Pregnant women at risk for hepatitis A during pregnancy should also be counseled concerning all options for preventing infection.
The most frequently reported adverse events associated with monovalent hepatitis A vaccination are fever, injection site reactions, and rash. Any adverse event suspected to be associated with hepatitis A vaccination should be reported through the Vaccine Adverse Event Reporting Systemexternal icon (VAERS).
Prevaccination serologic testing for hepatitis A immunity prior to vaccination is not routinely recommended. However, it may be considered in specific settings or populations when the cost of vaccinating people who are already immune is a concern. People for whom prevaccination testing will likely be most cost-effective include adults who were either born in or lived for extensive periods in geographic areas that have a high or intermediate endemicity of hepatitis A. Vaccination should not be postponed if vaccination history cannot be obtained, records are unavailable, or prevaccination testing is not feasible.
Serologic testing for immunity is not necessary after routine vaccination of infants, children, or adults. However, it may be considered in specific settings or populations when the cost of vaccinating people who are already immune is a concern. People for whom prevaccination testing will likely be most cost-effective include adults who were either born in or lived for extensive periods in geographic areas that have a high or intermediate endemicity of hepatitis A. Vaccination should not be postponed if vaccination history cannot be obtained, records are unavailable, or prevaccination testing is not feasible.
Because common-source transmission to patrons is unlikely, PEP administration to patrons is typically not indicated. However, PEP may be considered for those patrons potentially exposed to a symptomatic food handler if a) the food handler directly handled uncooked or cooked foods without gloves AND had diarrhea or poor hygienic practices and b) the patron can be identified and treated within 2 weeks of exposure, though the risk to these patrons still remains low (36). 041b061a72